Effect of small-molecule-binding affinity on tumor uptake in vivo: A systematic study using a pretargeted bispecific antibody

Molecular Cancer Therapeutics

Volumn 11, Issue 6, 2012, Pages 1365-1372

  Orcutt, Kelly Davis ^a   Rhoden, John J ^a   Ruiz Yi, Benjamin ^a   Frangioni, John V ^c   Wittrup, K Dane ^a,b  

^a USA   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; CARCINOEMBRYONIC ANTIGEN; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; IN VIVO STUDY; MATHEMATICAL MODEL; MOUSE; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STUDY DESIGN; TUMOR;

ANIMALS; ANTIBODIES, BISPECIFIC; CARCINOEMBRYONIC ANTIGEN; CELLS, CULTURED; CHELATING AGENTS; COORDINATION COMPLEXES; HAPTENS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INDIUM RADIOISOTOPES; LUTETIUM; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84862579971     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0764     Document Type: Article

References (40)

1. Beierwaltes WH. Radioiodine therapy of thyroid disease. Int J Rad Appl Instrum B 1987;14:177-81. (Pubitemid 17104837)
2. Britton KE. Towards the goal of cancer-specific imaging and therapy. Nucl Med Commun 1997;18:992-1007. (Pubitemid 27523980)
3. Firusian N, Mellin P, Schmidt CG. Results of 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol 1976;116:764-8. (Pubitemid 8009369)
4. Hoefnagel CA. Anti-cancer radiopharmaceuticals. Anticancer Drugs 1991;2:107-32.
5. Larson SM. Radioimmunology. Imaging and therapy. Cancer 1991;67:1253-60.
6. Winston MA. Radioisotope therapy in bone and joint disease. Semin Nucl Med 1979;9:114-20. (Pubitemid 9160589)
7. Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal anti-body. Clin Cancer Res 1999;5:3281s-6s. (Pubitemid 29493928)
8. Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 2007;67:2773-82. (Pubitemid 46548966)
9. Birchler MT, Thuerl C, Schmid D, Neri D, Waibel R, Schubiger A, et al. Immunoscintigraphy of patients with head and neck carcinomas, with an anti-angiogenetic antibody fragment. Otolaryngol Head Neck Surg 2007;136:543-8. (Pubitemid 46533872)
10. Reubi JC, Maecke HR. Peptide-based probes for cancer imaging. J Nucl Med 2008;49:1735-8.
11. Peng L, Liu R, Marik J, Wang X, Takada Y, Lam KS. Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2006;2:381-9. (Pubitemid 43936939)
12. Mammen M, Choi S, Whitesides GM. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 1998;37:2754-94. (Pubitemid 29008561)
13. Humblet V, Misra P, Bhushan KR, Nasr K, Ko YS, Tsukamoto T, et al. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting. J Med Chem 2009;52:544-50.
14. Misra P, Humblet V, Pannier N, Maison W, Frangioni JV. Production of multimeric prostate-specificmembrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med 2007;48:1379-89. (Pubitemid 47242804)
15. Goodwin DA, Meares CF, McCall MJ, McTigue M, Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J Nucl Med 1988;29:226-34. (Pubitemid 18056734)
16. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2005;11:7109s-21s. (Pubitemid 41428712)
17. Boerman OC, van Schaijk FG, Oyen WJ, Corstens FH. Pretargeted radioimmunotherapy of cancer: progress step by step. J Nucl Med 2003;44:400-11. (Pubitemid 39586017)
18. Orcutt KD, Slusarczyk AL, Cieslewicz M, Ruiz-Yi B, Bhushan KR, Frangioni JV, et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol 2011;38:223-33.
19. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010;23:221-8.
20. Humblet V, Misra P, Frangioni JV. An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives. Contrast Media Mol Imaging 2006;1:196-211.
21. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861-71.
22. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-32. (Pubitemid 29463104)
23. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84. (Pubitemid 30122932)
24. Hoppin J, Orcutt KD, Hesterman JY, Silva MD, Cheng D, Lackas C, et al. Assessing antibody pharmacokinetics in mice with in vivo imaging. J Pharmacol Exp Ther 2011;337:350-8.
25. Daldrup H, Shames DM, Wendland M, Okuhata Y, Link TM, RosenauW, et al. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. AJR Am J Roentgenol 1998;171:941-9. (Pubitemid 28449949)
26. Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med 1994;35:899-908. (Pubitemid 24151232)
27. Stein R, Govindan SV, Mattes MJ, Chen S, Reed L, Newsome G, et al. Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res 2003;63:111-8. (Pubitemid 36070428)
28. Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolismand retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123-9. (Pubitemid 26119913)
29. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5. (Pubitemid 32691886)
30. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011;71:2250-9.
31. Thurber GM, Zajic SC, Wittrup KD. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007;48:995-9. (Pubitemid 46909929)
32. Orcutt KD, Nasr K, Whitehead DG, Frangioni JV, Wittrup KD. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy. Mol Imaging Biol 2011;13:215-21.
33. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoem-bryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother 2008;57:1879-90.
34. van Gog FB, Visser GW, Gowrising RW, Snow GB, van Dongen GA. Synthesis and evaluation of 99mTc/99Tc-MAG3-biotin conjugates for antibody pretargeting strategies. Nucl Med Biol 1998;25:611-9. (Pubitemid 28442726)
35. van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, et al. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody. Clin Cancer Res 2005;11:7130s-6s. (Pubitemid 41428714)
36. Le Mignon MM, Chambon C, Warrington S, Davies R, Bonnemain B. Gd-DOTA. Pharmacokinetics and tolerability after intravenous injection into healthy volunteers. Invest Radiol 1990;25:933-7. (Pubitemid 20226829)
37. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, Goldenberg DM. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother 1991;33:351-8.
38. Sharkey RM, Karacay H, Johnson CR, Litwin S, Rossi EA,McBride WJ, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 2009;50:444-53.
39. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-5. (Pubitemid 43093674)
40. Sharkey RM, Karacay H, Vallabhajosula S, McBride WJ, Rossi EA, Chang CH, et al. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 2008;246:497-507.